Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 1503 entries
Sorted by: Best Match Show Resources per page
A rare presentation of primary leiomyosarcoma of ovary in a young woman.

Ecancermedicalscience

Vijaya Kumar J, Khurana A, Kaur P, Chuahan AK, Singh S.
PMID: 25932048
Ecancermedicalscience. 2015 Apr 21;9:524. doi: 10.3332/ecancer.2015.524. eCollection 2015.

Primary ovarian leiomyosarcoma is a very rare tumour which is most commonly seen in postmenopausal women. A case is described here involving a 30-year-old female who presented with pain in the abdomen. The patient underwent laparotomy with peritoneal lavage,...

Cite
Vijaya Kumar J, Khurana A, Kaur P, et al. A rare presentation of primary leiomyosarcoma of ovary in a young woman. Ecancermedicalscience. 2015;9:524doi: 10.3332/ecancer.2015.524.
Vijaya Kumar, J., Khurana, A., Kaur, P., Chuahan, A. K., & Singh, S. (2015). A rare presentation of primary leiomyosarcoma of ovary in a young woman. Ecancermedicalscience, 9524. https://doi.org/10.3332/ecancer.2015.524
Vijaya Kumar, J, et al. "A rare presentation of primary leiomyosarcoma of ovary in a young woman." Ecancermedicalscience vol. 9 (2015): 524. doi: https://doi.org/10.3332/ecancer.2015.524
Vijaya Kumar J, Khurana A, Kaur P, Chuahan AK, Singh S. A rare presentation of primary leiomyosarcoma of ovary in a young woman. Ecancermedicalscience. 2015 Apr 21;9:524. doi: 10.3332/ecancer.2015.524. eCollection 2015. PMID: 25932048; PMCID: PMC4406529.
Copy Download .nbib Format: NLM
Different types of cell cycle- and apoptosis-related gene expressions alter in corticosteroid-, vincristine-, and melphalan-resistant u-266 multiple myeloma cell lines.

Turkish journal of haematology : official journal of Turkish Society of Haematology

Mutlu P, Ural AU, Gündüz U.
PMID: 25330516
Turk J Haematol. 2014 Sep 05;31(3):231-8. doi: 10.4274/tjh.2013.0231.

OBJECTIVE: Hemophilia B is caused by coagulation defects in the factor IX gene located in Xq27.1 on the X chromosome. A wide range of mutations, showing extensive molecular heterogeneity, have been described in hemophilia B patients. Our study was...

Cite
Mutlu P, Ural AU, Gündüz U. Hücre Döngüsü ve Apoptoz ile İlgili Gen İfadelerinin Kortikosteroid, Vinkristin ve Melfalan Dirençli U-266 Multipl Myelom Hücre Hatlarında Analizi. Different types of cell cycle- and apoptosis-related gene expressions alter in corticosteroid-, vincristine-, and melphalan-resistant u-266 multiple myeloma cell lines. Turk J Haematol. 2014;31(3):231-8doi: 10.4274/tjh.2013.0231.
Mutlu, P., Ural, A. U., & Gündüz, U. (2014). Hücre Döngüsü ve Apoptoz ile İlgili Gen İfadelerinin Kortikosteroid, Vinkristin ve Melfalan Dirençli U-266 Multipl Myelom Hücre Hatlarında Analizi. Different types of cell cycle- and apoptosis-related gene expressions alter in corticosteroid-, vincristine-, and melphalan-resistant u-266 multiple myeloma cell lines. Turkish journal of haematology : official journal of Turkish Society of Haematology, 31(3), 231-8. https://doi.org/10.4274/tjh.2013.0231
Mutlu, Pelin, et al. "Hücre Döngüsü ve Apoptoz ile İlgili Gen İfadelerinin Kortikosteroid, Vinkristin ve Melfalan Dirençli U-266 Multipl Myelom Hücre Hatlarında Analizi." Different types of cell cycle- and apoptosis-related gene expressions alter in corticosteroid-, vincristine-, and melphalan-resistant u-266 multiple myeloma cell lines. Turkish journal of haematology : official journal of Turkish Society of Haematology vol. 31,3 (2014): 231-8. doi: https://doi.org/10.4274/tjh.2013.0231
Mutlu P, Ural AU, Gündüz U. Hücre Döngüsü ve Apoptoz ile İlgili Gen İfadelerinin Kortikosteroid, Vinkristin ve Melfalan Dirençli U-266 Multipl Myelom Hücre Hatlarında Analizi. Different types of cell cycle- and apoptosis-related gene expressions alter in corticosteroid-, vincristine-, and melphalan-resistant u-266 multiple myeloma cell lines. Turk J Haematol. 2014 Sep 05;31(3):231-8. doi: 10.4274/tjh.2013.0231. PMID: 25330516; PMCID: PMC4287023.
Copy Download .nbib Format: NLM
A novel use of early radiation therapy in the treatment of hyperbilirubinemia in a patient with primary hepatic lymphoma and chronic hepatitis C.

Case reports in gastrointestinal medicine

Tammana VS, Begum R, Oneal P, Karpurapu H, Muley A, Yeruva SL, Dunmore-Griffith J, Mekonen E, Hasan N.
PMID: 24872902
Case Rep Gastrointest Med. 2014;2014:724256. doi: 10.1155/2014/724256. Epub 2014 Apr 29.

Lymphomas arising in the liver are extremely rare. Here, we describe a case of Hepatitis C virus infection with primary hepatic lymphoma (PHL) presenting with hyperbilirubinemia. A 45-year-old African American male presented with abdominal pain, pruritus, and itching for...

Cite
Tammana VS, Begum R, Oneal P, et al. A novel use of early radiation therapy in the treatment of hyperbilirubinemia in a patient with primary hepatic lymphoma and chronic hepatitis C. Case Rep Gastrointest Med. 2014;2014:724256doi: 10.1155/2014/724256.
Tammana, V. S., Begum, R., Oneal, P., Karpurapu, H., Muley, A., Yeruva, S. L., Dunmore-Griffith, J., Mekonen, E., & Hasan, N. (2014). A novel use of early radiation therapy in the treatment of hyperbilirubinemia in a patient with primary hepatic lymphoma and chronic hepatitis C. Case reports in gastrointestinal medicine, 2014724256. https://doi.org/10.1155/2014/724256
Tammana, Venkata S, et al. "A novel use of early radiation therapy in the treatment of hyperbilirubinemia in a patient with primary hepatic lymphoma and chronic hepatitis C." Case reports in gastrointestinal medicine vol. 2014 (2014): 724256. doi: https://doi.org/10.1155/2014/724256
Tammana VS, Begum R, Oneal P, Karpurapu H, Muley A, Yeruva SL, Dunmore-Griffith J, Mekonen E, Hasan N. A novel use of early radiation therapy in the treatment of hyperbilirubinemia in a patient with primary hepatic lymphoma and chronic hepatitis C. Case Rep Gastrointest Med. 2014;2014:724256. doi: 10.1155/2014/724256. Epub 2014 Apr 29. PMID: 24872902; PMCID: PMC4020534.
Copy Download .nbib Format: NLM
Proapoptotic and Antiproliferative Effects of Thymus caramanicus on Human Breast Cancer Cell Line (MCF-7) and Its Interaction with Anticancer Drug Vincristine.

Evidence-based complementary and alternative medicine : eCAM

Esmaeili-Mahani S, Falahi F, Yaghoobi MM.
PMID: 24812569
Evid Based Complement Alternat Med. 2014;2014:893247. doi: 10.1155/2014/893247. Epub 2014 Apr 09.

Thymus caramanicus Jalas is one of the species of thymus that grows in the wild in different regions of Iran. Traditionally, leaves of this plant are used in the treatment of diabetes, arthritis, and cancerous situation. Therefore, the present...

Cite
Esmaeili-Mahani S, Falahi F, Yaghoobi MM. Proapoptotic and Antiproliferative Effects of Thymus caramanicus on Human Breast Cancer Cell Line (MCF-7) and Its Interaction with Anticancer Drug Vincristine. Evid Based Complement Alternat Med. 2014;2014:893247doi: 10.1155/2014/893247.
Esmaeili-Mahani, S., Falahi, F., & Yaghoobi, M. M. (2014). Proapoptotic and Antiproliferative Effects of Thymus caramanicus on Human Breast Cancer Cell Line (MCF-7) and Its Interaction with Anticancer Drug Vincristine. Evidence-based complementary and alternative medicine : eCAM, 2014893247. https://doi.org/10.1155/2014/893247
Esmaeili-Mahani, Saeed, et al. "Proapoptotic and Antiproliferative Effects of Thymus caramanicus on Human Breast Cancer Cell Line (MCF-7) and Its Interaction with Anticancer Drug Vincristine." Evidence-based complementary and alternative medicine : eCAM vol. 2014 (2014): 893247. doi: https://doi.org/10.1155/2014/893247
Esmaeili-Mahani S, Falahi F, Yaghoobi MM. Proapoptotic and Antiproliferative Effects of Thymus caramanicus on Human Breast Cancer Cell Line (MCF-7) and Its Interaction with Anticancer Drug Vincristine. Evid Based Complement Alternat Med. 2014;2014:893247. doi: 10.1155/2014/893247. Epub 2014 Apr 09. PMID: 24812569; PMCID: PMC4000631.
Copy Download .nbib Format: NLM
Short- and Long-term weight changes among United States veterans with diffuse large B-cell lymphoma treated with CHOP chemotherapy.

Leukemia & lymphoma

O'Brian K, Luo S, Ganti A, Riedell P, Lynch RC, Roop R, Sanfilippo KM, Liu W, Colditz GA, Carson KR.
PMID: 26085202
Leuk Lymphoma. 2016 Feb;57(2):313-319. doi: 10.3109/10428194.2015.1056183. Epub 2015 Jul 25.

Identifying weight changes associated with treatment of diffuse large B-cell lymphoma (DLBCL) has the potential to improve the long-term health of survivors. A retrospective cohort of United States veterans with a new diagnosis of DLBCL between October 1, 1998...

Cite
O'Brian K, Luo S, Ganti A, et al. Short- and Long-term weight changes among United States veterans with diffuse large B-cell lymphoma treated with CHOP chemotherapy. Leuk Lymphoma. 2015;57(2):313-319doi: 10.3109/10428194.2015.1056183.
O'Brian, K., Luo, S., Ganti, A., Riedell, P., Lynch, R. C., Roop, R., Sanfilippo, K. M., Liu, W., Colditz, G. A., & Carson, K. R. (2016). Short- and Long-term weight changes among United States veterans with diffuse large B-cell lymphoma treated with CHOP chemotherapy. Leukemia & lymphoma, 57(2), 313-319. https://doi.org/10.3109/10428194.2015.1056183
O'Brian, Katiuscia, et al. "Short- and Long-term weight changes among United States veterans with diffuse large B-cell lymphoma treated with CHOP chemotherapy." Leukemia & lymphoma vol. 57,2 (2016): 313-319. doi: https://doi.org/10.3109/10428194.2015.1056183
O'Brian K, Luo S, Ganti A, Riedell P, Lynch RC, Roop R, Sanfilippo KM, Liu W, Colditz GA, Carson KR. Short- and Long-term weight changes among United States veterans with diffuse large B-cell lymphoma treated with CHOP chemotherapy. Leuk Lymphoma. 2016 Feb;57(2):313-319. doi: 10.3109/10428194.2015.1056183. Epub 2015 Jul 25. PMID: 26085202; PMCID: PMC4752439.
Copy Download .nbib Format: NLM
Post-treatment PET-CT Findings may Predict the Prognosis of DLBCL with a Bulky Mass.

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion

Takasaki H, Yamamoto W, Ishii Y, Takahashi H, Watanabe R, Harada T, Kawasaki R, Hashimoto C, Motomura S, Tomita N, Ishigatsubo Y, Sakai R.
PMID: 26085719
Indian J Hematol Blood Transfus. 2015 Sep;31(3):346-51. doi: 10.1007/s12288-014-0479-9. Epub 2014 Dec 03.

We retrospectively analyzed the prognosis of patients with diffuse large B cell lymphoma (DLBCL) and a bulky mass at diagnosis. We retrospectively analyzed clinical data for 29 consecutive DLBCL patients with an initial bulky mass receiving R-CHOP (rituximab, cyclophosphamide,...

Cite
Takasaki H, Yamamoto W, Ishii Y, et al. Post-treatment PET-CT Findings may Predict the Prognosis of DLBCL with a Bulky Mass. Indian J Hematol Blood Transfus. 2014;31(3):346-51doi: 10.1007/s12288-014-0479-9.
Takasaki, H., Yamamoto, W., Ishii, Y., Takahashi, H., Watanabe, R., Harada, T., Kawasaki, R., Hashimoto, C., Motomura, S., Tomita, N., Ishigatsubo, Y., & Sakai, R. (2015). Post-treatment PET-CT Findings may Predict the Prognosis of DLBCL with a Bulky Mass. Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion, 31(3), 346-51. https://doi.org/10.1007/s12288-014-0479-9
Takasaki, Hirotaka, et al. "Post-treatment PET-CT Findings may Predict the Prognosis of DLBCL with a Bulky Mass." Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion vol. 31,3 (2015): 346-51. doi: https://doi.org/10.1007/s12288-014-0479-9
Takasaki H, Yamamoto W, Ishii Y, Takahashi H, Watanabe R, Harada T, Kawasaki R, Hashimoto C, Motomura S, Tomita N, Ishigatsubo Y, Sakai R. Post-treatment PET-CT Findings may Predict the Prognosis of DLBCL with a Bulky Mass. Indian J Hematol Blood Transfus. 2015 Sep;31(3):346-51. doi: 10.1007/s12288-014-0479-9. Epub 2014 Dec 03. PMID: 26085719; PMCID: PMC4465504.
Copy Download .nbib Format: NLM
Iatrogenic Coagulopathy and the Development of Posterior Reversible Encephalopathy Syndrome after L-asparaginase Chemotherapy.

Journal of clinical imaging science

Rota E, Vallisa D, Morelli N, Scagnelli P.
PMID: 27014503
J Clin Imaging Sci. 2016 Feb 26;6:7. doi: 10.4103/2156-7514.177553. eCollection 2016.

Posterior reversible encephalopathy syndrome (PRES) is a clinical and radiological syndrome mostly related to hypertension, eclampsia, renal failure, or to chemotherapy and/or immunosuppressive drugs. Although the PRES pathophysiology is multifactorial, hypertension and endothelial dysfunction are hypothesized to be the...

Cite
Rota E, Vallisa D, Morelli N, et al. Iatrogenic Coagulopathy and the Development of Posterior Reversible Encephalopathy Syndrome after L-asparaginase Chemotherapy. J Clin Imaging Sci. 2016;6:7doi: 10.4103/2156-7514.177553.
Rota, E., Vallisa, D., Morelli, N., & Scagnelli, P. (2016). Iatrogenic Coagulopathy and the Development of Posterior Reversible Encephalopathy Syndrome after L-asparaginase Chemotherapy. Journal of clinical imaging science, 67. https://doi.org/10.4103/2156-7514.177553
Rota, Eugenia, et al. "Iatrogenic Coagulopathy and the Development of Posterior Reversible Encephalopathy Syndrome after L-asparaginase Chemotherapy." Journal of clinical imaging science vol. 6 (2016): 7. doi: https://doi.org/10.4103/2156-7514.177553
Rota E, Vallisa D, Morelli N, Scagnelli P. Iatrogenic Coagulopathy and the Development of Posterior Reversible Encephalopathy Syndrome after L-asparaginase Chemotherapy. J Clin Imaging Sci. 2016 Feb 26;6:7. doi: 10.4103/2156-7514.177553. eCollection 2016. PMID: 27014503; PMCID: PMC4785783.
Copy Download .nbib Format: NLM
Diffuse large B-cell lymphoma presenting as bilateral renal infiltration leading to acute kidney injury.

CEN case reports

Okubo T, Hirashio S, Shimizu M, Kuroda Y, Doi S, Masaki T.
PMID: 28593485
CEN Case Rep. 2017 Nov;6(2):140-147. doi: 10.1007/s13730-017-0261-6. Epub 2017 Jun 07.

Acute kidney injury (AKI) because of bilateral renal infiltration is an uncommon presentation of diffuse large B-cell lymphoma (DLBCL). A 52-year-old man presented to our institution with AKI and complaints of fatigue. Ultrasonography revealed a large, 15 cm granulomatous...

Cite
Okubo T, Hirashio S, Shimizu M, et al. Diffuse large B-cell lymphoma presenting as bilateral renal infiltration leading to acute kidney injury. CEN Case Rep. 2017;6(2):140-147doi: 10.1007/s13730-017-0261-6.
Okubo, T., Hirashio, S., Shimizu, M., Kuroda, Y., Doi, S., & Masaki, T. (2017). Diffuse large B-cell lymphoma presenting as bilateral renal infiltration leading to acute kidney injury. CEN case reports, 6(2), 140-147. https://doi.org/10.1007/s13730-017-0261-6
Okubo, Tomoe, et al. "Diffuse large B-cell lymphoma presenting as bilateral renal infiltration leading to acute kidney injury." CEN case reports vol. 6,2 (2017): 140-147. doi: https://doi.org/10.1007/s13730-017-0261-6
Okubo T, Hirashio S, Shimizu M, Kuroda Y, Doi S, Masaki T. Diffuse large B-cell lymphoma presenting as bilateral renal infiltration leading to acute kidney injury. CEN Case Rep. 2017 Nov;6(2):140-147. doi: 10.1007/s13730-017-0261-6. Epub 2017 Jun 07. PMID: 28593485; PMCID: PMC5694399.
Copy Download .nbib Format: NLM
Rapid progression of Epstein-Barr-virus-positive gastric diffuse large B-cell lymphoma during chemoradiotherapy: a case report.

Clinical journal of gastroenterology

Sumida T, Kitadai Y, Masuda H, Shinagawa K, Tanaka M, Kodama M, Kuroda T, Hiyama T, Tanaka S, Nakayama H, Yoshihara M, Yoshino T, Chayama K.
PMID: 26193647
Clin J Gastroenterol. 2008 Oct;1(3):105-109. doi: 10.1007/s12328-008-0020-5. Epub 2008 Aug 12.

A 61-year-old woman was referred to our hospital with epigastralgia and appetite loss. Barium examination and upper gastrointestinal endoscopy revealed uneven erythematous mucosa with multiple elevated lesions from the gastric fornix to the upper corpus. Abdominal computed tomography showed...

Cite
Sumida T, Kitadai Y, Masuda H, et al. Rapid progression of Epstein-Barr-virus-positive gastric diffuse large B-cell lymphoma during chemoradiotherapy: a case report. Clin J Gastroenterol. 2008;1(3):105-109doi: 10.1007/s12328-008-0020-5.
Sumida, T., Kitadai, Y., Masuda, H., Shinagawa, K., Tanaka, M., Kodama, M., Kuroda, T., Hiyama, T., Tanaka, S., Nakayama, H., Yoshihara, M., Yoshino, T., & Chayama, K. (2008). Rapid progression of Epstein-Barr-virus-positive gastric diffuse large B-cell lymphoma during chemoradiotherapy: a case report. Clinical journal of gastroenterology, 1(3), 105-109. https://doi.org/10.1007/s12328-008-0020-5
Sumida, Tomonori, et al. "Rapid progression of Epstein-Barr-virus-positive gastric diffuse large B-cell lymphoma during chemoradiotherapy: a case report." Clinical journal of gastroenterology vol. 1,3 (2008): 105-109. doi: https://doi.org/10.1007/s12328-008-0020-5
Sumida T, Kitadai Y, Masuda H, Shinagawa K, Tanaka M, Kodama M, Kuroda T, Hiyama T, Tanaka S, Nakayama H, Yoshihara M, Yoshino T, Chayama K. Rapid progression of Epstein-Barr-virus-positive gastric diffuse large B-cell lymphoma during chemoradiotherapy: a case report. Clin J Gastroenterol. 2008 Oct;1(3):105-109. doi: 10.1007/s12328-008-0020-5. Epub 2008 Aug 12. PMID: 26193647.
Copy Download .nbib Format: NLM
Effects of survivin on FVADT chemotherapy for refractory multiple myeloma.

Experimental and therapeutic medicine

Yang H, Du X, Xi Y.
PMID: 27446274
Exp Ther Med. 2016 Aug;12(2):771-776. doi: 10.3892/etm.2016.3401. Epub 2016 May 26.

The present study aimed to investigate the effects of survivin, an apoptosis inhibitor protein, on the efficacy of the fludarabine, vincristine, epirubicin, dexamethasone and thalidomide (FVADT) chemotherapy regime for the treatment of refractory multiple myeloma (MM). A total of...

Cite
Yang H, Du X, Xi Y. Effects of survivin on FVADT chemotherapy for refractory multiple myeloma. Exp Ther Med. 2016;12(2):771-776doi: 10.3892/etm.2016.3401.
Yang, H., Du, X., & Xi, Y. (2016). Effects of survivin on FVADT chemotherapy for refractory multiple myeloma. Experimental and therapeutic medicine, 12(2), 771-776. https://doi.org/10.3892/etm.2016.3401
Yang, Hua, et al. "Effects of survivin on FVADT chemotherapy for refractory multiple myeloma." Experimental and therapeutic medicine vol. 12,2 (2016): 771-776. doi: https://doi.org/10.3892/etm.2016.3401
Yang H, Du X, Xi Y. Effects of survivin on FVADT chemotherapy for refractory multiple myeloma. Exp Ther Med. 2016 Aug;12(2):771-776. doi: 10.3892/etm.2016.3401. Epub 2016 May 26. PMID: 27446274; PMCID: PMC4950835.
Copy Download .nbib Format: NLM
Vincristine, Adriamycin and Dexamethasone (VAD) as Primary Therapy in Advanced Multiple Myeloma: A Single Centre Experience.

Leukemia & lymphoma

Macphail AP, Weaving A, Bezwoda WR.
PMID: 27457443
Leuk Lymphoma. 1990;3(3):227-30. doi: 10.3109/10428199009051001.

Vincristine, adriamycin and dexamethasone (VAD) combination chemotherapy was used as first line therapy in eleven patients with severe myeloma. Eight patients (73%) responded to VAD, six of them achieved complete remission (55%) with paraprotein concentrations falling to zero after...

Cite
Macphail AP, Weaving A, Bezwoda WR. Vincristine, Adriamycin and Dexamethasone (VAD) as Primary Therapy in Advanced Multiple Myeloma: A Single Centre Experience. Leuk Lymphoma. 1990;3(3):227-30doi: 10.3109/10428199009051001.
Macphail, A. P., Weaving, A., & Bezwoda, W. R. (1990). Vincristine, Adriamycin and Dexamethasone (VAD) as Primary Therapy in Advanced Multiple Myeloma: A Single Centre Experience. Leukemia & lymphoma, 3(3), 227-30. https://doi.org/10.3109/10428199009051001
Macphail, A P, et al. "Vincristine, Adriamycin and Dexamethasone (VAD) as Primary Therapy in Advanced Multiple Myeloma: A Single Centre Experience." Leukemia & lymphoma vol. 3,3 (1990): 227-30. doi: https://doi.org/10.3109/10428199009051001
Macphail AP, Weaving A, Bezwoda WR. Vincristine, Adriamycin and Dexamethasone (VAD) as Primary Therapy in Advanced Multiple Myeloma: A Single Centre Experience. Leuk Lymphoma. 1990;3(3):227-30. doi: 10.3109/10428199009051001. PMID: 27457443.
Copy Download .nbib Format: NLM
Enhancing Effects of Curcumin on Cytotoxicity of Paclitaxel, Methotrexate and Vincristine in Gastric Cancer Cells.

Asian Pacific journal of cancer prevention : APJCP

Ebrahimifar M, Hasanzadegan Roudsari M, Kazemi SM, Ebrahimi Shahmabadi H, Kanaani L, Alavi SA, Izadi Vasfi M.
PMID: 28240011
Asian Pac J Cancer Prev. 2017 Jan 01;18(1):65-68. doi: 10.22034/APJCP.2017.18.1.65.

Curcumin (Diferuloylmethane), a polyphenolic compound with antioxidant, anti-inflammatory and anticancer properties, has been found to increase chemotherapeutic agents-induced cytotoxicity in some resistant cancer cell lines. This investigation aimed to study the effects of curcumin on efficacy of some common...

Cite
Ebrahimifar M, Hasanzadegan Roudsari M, Kazemi SM, et al. Enhancing Effects of Curcumin on Cytotoxicity of Paclitaxel, Methotrexate and Vincristine in Gastric Cancer Cells. Asian Pac J Cancer Prev. 2017;18(1):65-68doi: 10.22034/APJCP.2017.18.1.65.
Ebrahimifar, M., Hasanzadegan Roudsari, M., Kazemi, S. M., Ebrahimi Shahmabadi, H., Kanaani, L., Alavi, S. A., & Izadi Vasfi, M. (2017). Enhancing Effects of Curcumin on Cytotoxicity of Paclitaxel, Methotrexate and Vincristine in Gastric Cancer Cells. Asian Pacific journal of cancer prevention : APJCP, 18(1), 65-68. https://doi.org/10.22034/APJCP.2017.18.1.65
Ebrahimifar, Meysam, et al. "Enhancing Effects of Curcumin on Cytotoxicity of Paclitaxel, Methotrexate and Vincristine in Gastric Cancer Cells." Asian Pacific journal of cancer prevention : APJCP vol. 18,1 (2017): 65-68. doi: https://doi.org/10.22034/APJCP.2017.18.1.65
Ebrahimifar M, Hasanzadegan Roudsari M, Kazemi SM, Ebrahimi Shahmabadi H, Kanaani L, Alavi SA, Izadi Vasfi M. Enhancing Effects of Curcumin on Cytotoxicity of Paclitaxel, Methotrexate and Vincristine in Gastric Cancer Cells. Asian Pac J Cancer Prev. 2017 Jan 01;18(1):65-68. doi: 10.22034/APJCP.2017.18.1.65. PMID: 28240011; PMCID: PMC5563121.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 1503 entries